Home | Terms of Use | Privacy Statement | Contact Us For U.S. healthcare professionals only.
		Prescribing Information   Video Watch a Biological  Video online...   We are truly sorry that information is missing here. We are currently working on this piece of information and it will be available as soon as possible. Please come back soon!
	Kepivance® is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. The safety and efficacy of Kepivance® have not been established in patients with non-hematologic malignancies. Important Safety Information In patients with hematologic malignancies, the most common serious adverse reaction in clinical trials attributed to Kepivance® was skin rash reported in less than 1% of patients.   Contact | Reimbursement | Biovitrum.com | Site Map Prescribing Information © 2008 Biovitrum AB (publ). All rights reserved.